PAM
VIVO

Paradigm Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Paradigm Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,600
Closed -$275K – 856
2014
Q1 		$275K Sell
12,600
-1,000
-7% -$22.9K 0.04% 448
2013
Q4 		$361K Sell
13,600
-1,400
-9% -$34.4K 0.06% 397
2013
Q3 		$355K Buy
+15,000
New +$350K 0.06% 369

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
PIM
Perkins Investment Management Chicago, Illinois $8.09B AUM 25.47% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paradigm Asset Management's VIVO Position: Q2 2014 in Review

Paradigm Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2014, closing a stake of 12,600 shares — an estimated $275K sold.

Paradigm Asset Management first reported a position in VIVO in Q3 2013 and held it in 3 quarters. The position peaked at $361K in Q4 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q2 2014.

  • Paradigm Asset Management reported no remaining Meridian Bioscience Inc position as of Q2 2014 after selling out during the quarter.
  • Paradigm Asset Management sold 12,600 Meridian Bioscience Inc shares in Q2 2014, an estimated $275K.
  • Paradigm Asset Management first reported a position in Meridian Bioscience Inc in Q3 2013 and held it in 3 quarters.
  • Paradigm Asset Management's Meridian Bioscience Inc position peaked at $361K in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2014.

Based on Paradigm Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.